TY - JOUR
T1 - Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure
AU - Lei, Biao
AU - Lionetti, Vincenzo
AU - Young, Martin E.
AU - Chandler, Margaret P.
AU - D'Agostino, Chiara
AU - Kang, Elaine
AU - Altarejos, Martin
AU - Matsuo, Ken
AU - Hintze, Thomas H.
AU - Stanley, William C.
AU - Recchia, Fabio A.
N1 - Funding Information:
This study was supported by the National Heart, Lung and Blood Institute grant RO1 HL-62573 (F.A. Recchia) and in part by PO1 HL-43023 (T.H. Hintze), and PO1 HL-74237 (W.C. Stanley and F.A. Recchia). This study was also supported in part by the American Heart Association Texas Affiliate grant 0365028Y (M.E. Young).
PY - 2004/4
Y1 - 2004/4
N2 - Free fatty acid (FFA) oxidation is depressed in severe heart failure due to reduced activity of mitochondrial fatty acid oxidation enzymes. It is unknown whether the concomitant enhancement in cardiac glucose use is a consequence of reduced FFA oxidation, or also due to potentiation of the carbohydrate oxidative pathway. FFA and glucose oxidation rates were measured in vivo in 9 normal dogs and 9 dogs with pacing-induced heart failure by infusing 3H-oleate and 14C-glucose. FFA oxidation was lower (39 ± 9 vs. 73 ± 5 nmol min-1 g-1), while glucose oxidation was higher (42 ± 8 vs. 17 ± 6 nmol min-1 g-1) in failing compared to normal hearts (P < 0.05). At the end of the in vivo experiment, clamp-frozen biopsies were harvested from the left ventricle. Messenger RNAs encoding for proteins involved in both glucose and fatty acid metabolism, and for citrate synthase, were significantly reduced. Protein expression of GLUT-1 and GLUT-4, and GLUT-4 translocation to the sarcolemma showed no significant differences between the two groups despite a significant reduction in mRNAs with heart failure. GAPDH mRNA, protein expression, and activity were all reduced. The E2 subunit of pyruvate dehydrogenase was decreased both at the mRNA and protein level, with no effect on either fractional or maximal activity. In conclusion, we found either no changes or moderate downregulation of key enzymes of the carbohydrate metabolism in failing hearts, which suggests that the increase in glucose oxidation in vivo was principally due to impaired FFA oxidation and that the maximal myocardial capacity to obtain energy from substrate is globally depressed.
AB - Free fatty acid (FFA) oxidation is depressed in severe heart failure due to reduced activity of mitochondrial fatty acid oxidation enzymes. It is unknown whether the concomitant enhancement in cardiac glucose use is a consequence of reduced FFA oxidation, or also due to potentiation of the carbohydrate oxidative pathway. FFA and glucose oxidation rates were measured in vivo in 9 normal dogs and 9 dogs with pacing-induced heart failure by infusing 3H-oleate and 14C-glucose. FFA oxidation was lower (39 ± 9 vs. 73 ± 5 nmol min-1 g-1), while glucose oxidation was higher (42 ± 8 vs. 17 ± 6 nmol min-1 g-1) in failing compared to normal hearts (P < 0.05). At the end of the in vivo experiment, clamp-frozen biopsies were harvested from the left ventricle. Messenger RNAs encoding for proteins involved in both glucose and fatty acid metabolism, and for citrate synthase, were significantly reduced. Protein expression of GLUT-1 and GLUT-4, and GLUT-4 translocation to the sarcolemma showed no significant differences between the two groups despite a significant reduction in mRNAs with heart failure. GAPDH mRNA, protein expression, and activity were all reduced. The E2 subunit of pyruvate dehydrogenase was decreased both at the mRNA and protein level, with no effect on either fractional or maximal activity. In conclusion, we found either no changes or moderate downregulation of key enzymes of the carbohydrate metabolism in failing hearts, which suggests that the increase in glucose oxidation in vivo was principally due to impaired FFA oxidation and that the maximal myocardial capacity to obtain energy from substrate is globally depressed.
UR - http://www.scopus.com/inward/record.url?scp=11144354639&partnerID=8YFLogxK
U2 - 10.1016/j.yjmcc.2004.02.004
DO - 10.1016/j.yjmcc.2004.02.004
M3 - Article
C2 - 15081316
AN - SCOPUS:11144354639
SN - 0022-2828
VL - 36
SP - 567
EP - 576
JO - Journal of Molecular and Cellular Cardiology
JF - Journal of Molecular and Cellular Cardiology
IS - 4
ER -